IGF1 and Parkinson disease: Furthermore, behavioral recovery was observed after peripheral administration of IGF-1 in a 6-hydroxydopamine (6-OHDA) lesioned rat model of PD.[8] Indeed, a number of recent investigations have been conducted to evaluate serum IGF-1 levels among de novo, drug-naïve Parkinson’s disease patients versus healthy controls.